Ghosh S - Search Results

1

Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.

Lanzarotto F, Carpani M, Chaudhary R, Ghosh S. Lanzarotto F, et al. Among authors: ghosh s. Drugs. 2006;66(9):1179-89. doi: 10.2165/00003495-200666090-00002. Drugs. 2006. PMID: 16827596 Review.

2

Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab.

Ghosh S. Ghosh S. Expert Opin Biol Ther. 2003 Sep;3(6):995-1000. doi: 10.1517/14712598.3.6.995. Expert Opin Biol Ther. 2003. PMID: 12943458 Review.

3

Infliximab in refractory coeliac disease.

Chaudhary R, Ghosh S. Chaudhary R, et al. Among authors: ghosh s. Eur J Gastroenterol Hepatol. 2005 Jun;17(6):603-4. doi: 10.1097/00042737-200506000-00002. Eur J Gastroenterol Hepatol. 2005. PMID: 15879720 Review.

4

Hepatosplenic T cell lymphoma in inflammatory bowel disease.

Shale M, Kanfer E, Panaccione R, Ghosh S. Shale M, et al. Among authors: ghosh s. Gut. 2008 Dec;57(12):1639-41. doi: 10.1136/gut.2008.163279. Epub 2008 Jul 30. Gut. 2008. PMID: 18667489 No abstract available.

5

Beyond TNF, Th1 and Th2 in inflammatory bowel disease.

Shale M, Ghosh S. Shale M, et al. Among authors: ghosh s. Gut. 2008 Oct;57(10):1349-51. doi: 10.1136/gut.2008.151563. Gut. 2008. PMID: 18791115 No abstract available.

6

Characterization of inflammatory bowel disease with urinary metabolic profiling.

Williams HR, Cox IJ, Walker DG, North BV, Patel VM, Marshall SE, Jewell DP, Ghosh S, Thomas HJ, Teare JP, Jakobovits S, Zeki S, Welsh KI, Taylor-Robinson SD, Orchard TR. Williams HR, et al. Among authors: ghosh s. Am J Gastroenterol. 2009 Jun;104(6):1435-44. doi: 10.1038/ajg.2009.175. Epub 2009 Apr 28. Am J Gastroenterol. 2009. PMID: 19491857

7

Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.

Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart A, Hamlin J, Orchard T, Arebi N, Nightingale J, Jacyna MR, Gabe SM, O'Connor M, Harris AW, O'Morain C, Ghosh S. Russo EA, et al. Among authors: ghosh s. Eur J Gastroenterol Hepatol. 2010 Mar;22(3):334-9. doi: 10.1097/MEG.0b013e32832b20d4. Eur J Gastroenterol Hepatol. 2010. PMID: 19528808

8

Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain.

Akbar A, Yiangou Y, Facer P, Brydon WG, Walters JR, Anand P, Ghosh S. Akbar A, et al. Among authors: ghosh s. Gut. 2010 Jun;59(6):767-74. doi: 10.1136/gut.2009.194449. Gut. 2010. PMID: 20551462

9

NOD2 activity modulates the phenotype of LPS-stimulated dendritic cells to promote the development of T-helper type 2-like lymphocytes - Possible implications for NOD2-associated Crohn's disease.

Butler M, Chaudhary R, van Heel DA, Playford RJ, Ghosh S. Butler M, et al. Among authors: ghosh s. J Crohns Colitis. 2007 Dec;1(2):106-15. doi: 10.1016/j.crohns.2007.08.006. Epub 2007 Sep 27. J Crohns Colitis. 2007. PMID: 21172192

10

Natalizumab for active Crohn's disease.

Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S; Natalizumab Pan-European Study Group. Ghosh S, et al. N Engl J Med. 2003 Jan 2;348(1):24-32. doi: 10.1056/NEJMoa020732. N Engl J Med. 2003. PMID: 12510039 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13,257 results

Search Page